Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

June 10, 2025

CEO and members of Egetis’ Leadership Team acquire shares in Egetis

Read more

Regulatory

May 6, 2025

Bulletin from Egetis Therapeutics’ Annual General Meeting 2025

Read more

May 5, 2025

Egetis Confirms Launch of Emcitate® in Germany

Read more

Upcoming event

August 21, 2025

Interim Report Q2 2025 (7:00am CEST)

Latest presentation

April 30, 2025

Interim report Q1 2025 (webcast)

Latest Report

April 30, 2025

Interim report Q1 2025

Calendar and upcoming reports

August 21, 2025

Interim Report Q2 2025 (7:00am CEST)

November 7, 2025

Interim Report Q3 2025 (7:00am CET)

Joshua’s Story

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]